3 results
The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…
In patients with severe asthma and high eosinophil counts (>=250 cells/µl) receiving SoC asthma therapy, to demonstrate the efficacy (as measuredby rate of moderate-to-severe asthma exacerbations) of at least one dose level of QAW039 (150 mg…
To study the effects of left ventricular unloading by means of IABP or Impella as an adjunct to ECMO versus ECMO alone on ECMO weaning success, mortality, quality of life and cost-effectiveness, and intermediating physiological parameters.…